Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically disorder, Parkinson's disease, and manifest idiopathic REM sleep behavior controls
Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically disorder, Parkinson's disease, and manifest idiopathic REM sleep behavior controls
复制标题
DOI：
10.1093/sleep/26.5.507
复制
发表时间：
2003-08-01
期刊：
影响因子：
5.6
通讯作者：
Noachtar, S
中科院分区：
文献类型：
--
作者：
Eisensehr, I;Linke, R;Noachtar, S
目的：快速眼动（REM）睡眠行为障碍（RBD）是以REM睡眠期复杂行为为特征的疾病。这种疾病的病因仍然是未知的，但最近的一项研究表明，RBD先于帕金森病（PD）的症状几年，在以前的研究中，我们发现减少纹状体多巴胺转运蛋白在特发性临床表现RBD。设计：假设亚临床RBD显示纹状体多巴胺转运蛋白的减少不如临床表现的RBD严重，我们研究了纹状体突触后多巴胺D2受体与（S）-2羟基-3碘-6-甲氧基，用碘123（IBZM）标记的（[1-乙基-2-吡咯烷基]甲基）苯甲酰胺和用（N）-（3-碘丙烯-2-基）-2 β-甲氧羰基-3 β-在以下组中使用单光子发射计算机断层扫描（SPECT）进行碘123（IPT）标记的（4-氯苯基）托烷：8例特发性亚临床RBD患者，8例特发性临床表现RBD患者，11例对照，8例PD分期Hoehn & Yahr 1。对照组的IPT摄取最高。从对照组到亚临床RBD患者，从亚临床RBD患者到临床表现RBD患者，以及从临床表现RBD患者到PD患者，IPT摄取显著降低（对照组：右侧= 4.07 +/- 0.29，左侧= 4.07 +/- 0.30;亚临床RBD：右侧= 3.56 +/- 0.21，左侧= 3.55 +/- 0.25;临床表现RBD：右侧= 3.18 +/- 0.43，左侧3.2 +/- 0.43; PD：临床受累体侧同侧3.25 +/- 0.35，临床受累体侧对侧= 2.51 +/- 0.28）。持续超过0.5秒的REM睡眠期间的肌肉活动与纹状体多巴胺转运蛋白的减少独立相关（P=0.001）。IBZM摄取组之间没有显着差异groups.Conclusions：这项研究表明，有一个连续的减少纹状体多巴胺转运蛋白参与的病理生理机制，导致增加的肌肉活动在REM睡眠中的亚临床RBD患者。关键词：突触前多巴胺转运蛋白，突触后D2受体，REM睡眠行为障碍，帕金森病引用：Eisensehr 1; Linke R，- Tatsch K等人，在快速眼动睡眠期间增加的肌肉活动与纹状体突触前多巴胺转运蛋白的减少相关。亚临床和临床表现的特发性REM睡眠行为障碍、帕金森病和对照组的IPT和IBZM SPECT成像。
Objectives: Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by complex behavior during REM sleep. The etiology of this disorder is still unknown, but a recent study showed that RBD precedes symptoms of Parkinson disease (PD) by several years, and in a previous study, we found reduced striatal dopamine transporters in idiopathic clinically manifest RBD.Design: Hypothesizing that subclinical RBD shows a less severe reduction of striatal dopamine transporters than clinically manifest RBD, we studied striatal postsynaptic dopamine D2-receptors with (S)-2hydroxy-3iodo-6-methoxy-([1-ethyl-2-pyrrolidinyl]methyl) benzamide labeled with iodine 123 (IBZM) and the striatal presynaptic dopamine transporters with (N)-(3-iodopropene-2-yl)-2beta-carbomethoxy-3beta-(4-chlorophenyl) tropane labeled with iodine 123 (IPT) using single-photon emission computed tomography (SPECT) in the following groups: 8 patients with idiopathic subclinical RBD, 8 patients with idiopathic clinically manifest RBD, 11 controls, and 8 patients with PD stage Hoehn & Yahr 1.Results: The IPT uptake was highest in controls. There was a significant decrease in IPT uptake from controls to patients with subclinical RBD, from patients with subclinical RBD to clinically manifest RBD, and from patients with clinically manifest RBD to patients with PD (controls: right = 4.07 +/- 0.29, left = 4.07 +/- 0.30; subclinical RBD: right = 3.56 +/- 0.21, left = 3.55 +/- 0.25; clinically manifest RBD: right = 3.18 +/- 0.43, left 3.2 +/- 0.43; PD: ipsilateral to the clinically affected body side 3.25 +/- 0.35, contralateral to the clinically affected body side = 2.51 +/- 0.28). Muscle activity during REM sleep lasting persistently longer than 0.5 seconds was independently associated with reduction of striatal dopamine transporters (P=0.001). The IBZM uptake was not significantly different between the groups.Conclusions: This study suggests that there is a continuum of reduced striatal dopamine transporters involved in the pathophysiologic mechanisms causing increased muscle activity during REM sleep in patients with subclinical RBD. Key Words: presynaptic dopamine transporter, postsynaptic D2-receptor, REM sleep behavior disorder, Parkinson disease Citation: Eisensehr 1; Linke R,- Tatsch K et al. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, parkinson's disease, and controls.